NASDAQ:ENOB Enochian Biosciences (ENOB) Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.40▼$0.7952-Week Range N/AVolume88,300 shsAverage Volume137,347 shsMarket Capitalization$40.80 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainabilityProfileEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability About Enochian Biosciences (NASDAQ:ENOB) StockEnochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), and cancer. The company's product pipeline includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a gene therapy curative treatment for HBV. It develops ENOB-DC-11, an allogeneic dendritic cell therapeutic vaccine for solid tumors; ENOB-DC-12-XX, allogeneic dendritic cell therapeutic vaccine for other solid tumors; and ENOB-HV-21 for treating HIV with allogeneic natural killer (NK) and gamma delta T-cells. Enochian Biosciences, Inc. has strategic partnerships with the University of California, Fred Hutchinson Cancer Research Center, and Caring Cross. The company was incorporated in 2017 and is headquartered in Los Angeles, California.Read More ENOB Stock News HeadlinesSeptember 11, 2023 | barrons.comRenovaro Biosciences Inc.September 3, 2023 | investing.comRenovaro Biosciences Inc (RENB)September 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 21, 2023 | finance.yahoo.comRenovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical OfficerAugust 10, 2023 | finance.yahoo.comRenovaro BioSciences, GEDi Cube Announce LOI to Merge, Focus on Fight Against CancerAugust 9, 2023 | finance.yahoo.comAI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against CancerJuly 25, 2023 | finance.yahoo.com3 Doomed Biotech Stocks Destined for DisasterJune 23, 2023 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder MeetingSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."June 23, 2023 | finance.yahoo.comEnochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder MeetingJune 8, 2023 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA ReviewJune 8, 2023 | finance.yahoo.comEnochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA ReviewApril 15, 2023 | markets.businessinsider.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Enochian Biosciences Inc. (ENOB)April 3, 2023 | finance.yahoo.comEnochian BioSciences’ CEO Letter to ShareholdersMarch 29, 2023 | finance.yahoo.comEnochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading ResearcherMarch 13, 2023 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsMarch 13, 2023 | msn.comEnochian BioSciences regains Nasdaq compliance by filing pending reportsMarch 13, 2023 | finance.yahoo.comEnochian BioSciences Achieves Full Compliance with NASDAQ Filing RequirementsFebruary 23, 2023 | msn.comEnochian gets Nasdaq listing deficiency notice for not filing 10-QFebruary 23, 2023 | finance.yahoo.comEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended December 31, 2022January 19, 2023 | reuters.comENOB.O - | Stock Price & Latest News | ReutersNovember 30, 2022 | seekingalpha.comEnochian gets Nasdaq notice for delaying crucial filingsNovember 30, 2022 | finance.yahoo.comEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Form 10-Q for the Period Ended September 30, 2022October 24, 2022 | finance.yahoo.comBiotech Co-Founder, Facing Murder-for-Hire Charges, Accused of Fabricating DataOctober 24, 2022 | finance.yahoo.comEnochian BioSciences Forges Ahead With Focused Approach, Promising FutureOctober 21, 2022 | finance.yahoo.comEnochian BioSciences Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Annual Report on Form 10-KOctober 19, 2022 | finanznachrichten.deEnochian BioSciences, Inc.: Enochian BioSciences Awarded U.S. Patent For Its Promising Oncology PlatformSee More Headlines Receive ENOB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enochian Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ENOB Company Calendar Today9/27/2023Fiscal Year End6/30/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENOB CUSIPN/A CIK1527728 Webwww.enochianbio.com Phone(305) 918-1980FaxN/AEmployees22Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-154.69% Return on Assets-130.66% Debt Debt-to-Equity RatioN/A Current Ratio0.33 Quick Ratio0.33 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / BookN/AMiscellaneous Outstanding Shares58,280,000Free Float45,625,000Market Cap$40.80 million OptionableNot Optionable Beta1.09 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. Mark R. Dybul M.D. (Age 60)CEO, Director & Member of HBV Scientific Advisory Board Comp: $950kMs. Luisa Puche (Age 59)CFO & Corp. Sec. Comp: $403.75kDr. Serhat GümrükcüCo-Founder & InventorDr. Francois Binette M.Sc. (Age 59)Ph.D., Chief Operating Officer Mr. Greg Duczynski Ph.D.Sr. VP for Clinical OperationsKey CompetitorsGain TherapeuticsNASDAQ:GANXCytoMed TherapeuticsNASDAQ:GDTCDaré BioscienceNASDAQ:DARESocietal CDMONASDAQ:SCTLCoya TherapeuticsNASDAQ:COYAView All CompetitorsInstitutional OwnershipGoldman Sachs Group Inc.Bought 104,273 shares on 8/15/2023Ownership: 0.203%State Street CorpSold 255,321 shares on 8/14/2023Ownership: 0.089%Houlihan Financial Resource Group Ltd.Bought 201,500 shares on 8/2/2023Ownership: 0.346%View All Institutional Transactions ENOB Stock - Frequently Asked Questions What other stocks do shareholders of Enochian Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enochian Biosciences investors own include AcelRx Pharmaceuticals (ACRX), Aptinyx (APTX), Axcella Health (AXLA), Aytu BioPharma (AYTU), Calithera Biosciences (CALA), Cidara Therapeutics (CDTX), Catalyst Pharmaceuticals (CPRX), DURECT (DRRX), Geron (GERN) and What is Enochian Biosciences' stock symbol? Enochian Biosciences trades on the NASDAQ under the ticker symbol "ENOB." Who are Enochian Biosciences' major shareholders? Enochian Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Houlihan Financial Resource Group Ltd. (0.35%), Goldman Sachs Group Inc. (0.20%) and State Street Corp (0.09%). Insiders that own company stock include Carl Forest Sandler and Serhat Gumrukcu. View institutional ownership trends. How much money does Enochian Biosciences make? Enochian Biosciences (NASDAQ:ENOB) has a market capitalization of $0.00. How can I contact Enochian Biosciences? Enochian Biosciences' mailing address is 2080 Century Park EastSuite 906, Los Angeles CA, 90067. The official website for the company is www.enochianbio.com. The company can be reached via phone at (305) 918-1980 or via email at ir@enochianbio.com. This page (NASDAQ:ENOB) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enochian Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.